Triptans, such as sumatriptan, are selective serotonin receptor agonists that bind to 5-HT1B/1D receptors in cerebral vasculature, causing vasoconstriction and inhibiting neuropeptide release. When discontinuing triptan treatment for cluster headache, patients may experience potential rebound headaches or withdrawal symptoms due to the medication's direct impact on serotonergic neurotransmission. Gradual tapering under medical supervision is recommended to minimize potential neurological and vascular readjustment effects.